Biointron, established in 2012 and ISO 9001:2015 certified, is a leading Contract Research Organization (CRO) specializing in antibody discovery, optimization, and expression services for biotech and pharmaceutical companies worldwide.
Leveraging over a decade of experience, we have developed a high-throughput (HTP) recombinant antibody production platform that delivers purified antibodies from gene sequences in just two weeks.
This accelerated timeline is achieved through a streamlined workflow encompassing in-house gene synthesis, plasmid construction, transient expression in HEK293 or CHO cells, and stringent quality control measures. The process begins with codon optimization and gene synthesis, followed by subcloning into an expression vector. After plasmid amplification, transient transfection of mammalian cells is performed, leading to antibody expression and subsequent purification. Quality control includes SDS-PAGE analysis to ensure purity exceeds 95%, low endotoxin levels, and size-exclusion high-performance liquid chromatography (SEC-HPLC) detection.
Our commitment to rapid and reliable antibody production has attracted over 2,000 global biotech and pharmaceutical partners, including industry leaders such as AstraZeneca, AbbVie, Moderna, Sanofi, and Merck KGaA. These collaborations underscore Biointron's reputation for delivering high-quality antibodies with minimal batch-to-batch variation, meeting stringent industry standards.
In addition to recombinant antibody production, we offer a comprehensive suite of services, including bispecific antibody production, large-scale antibody production, protein expression in mammalian systems, single B-cell screening, CHO-K1 stable cell line generation, VHH antibody discovery, antibody humanization, and affinity maturation. This extensive service portfolio positions Biointron as a one-stop solution for antibody discovery and optimization needs.
Biointron's dedication to excellence, customer-centric approach, and passion for advancing biotechnology make it a trusted partner for researchers and developers seeking efficient and high-quality antibody solutions. Contact us at info@biointron.com or +1 (732) 790-8340.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
